Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bicycle Therapeutics plc - American Depositary Shares (NQ:BCYC)

7.070 +0.050 (+0.71%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bicycle Therapeutics plc - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 Next >
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
Stratasys, MillerKnoll, Nikola And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded higher, with the Nasdaq Composite gaining over 100 points on Thursday. Here are some big stocks recording gains in today’s session. Nikola Corporation (NASDAQ: NKLA) gained 18% to... 
Via Benzinga
Bicycle Therapeutics Announces Pricing of $200 Million Public Offering of American Depositary Shares and Non-Voting Ordinary Shares
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics's Return On Capital Employed Insights
 
Via Benzinga
Bicycle Therapeutics PLC (NASDAQ: BCYC) Making Surprising Moves in Friday Session
Via Investor Brand Network
14 Analysts Have This to Say About Bicycle Therapeutics
 
Via Benzinga
Recap: Bicycle Therapeutics Q1 Earnings
 
Via Benzinga
Bicycle Therapeutics Announces Proposed $200 Million Public Offering of American Depositary Shares and Non-Voting Ordinary Shares
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Appoints Alethia Young as Chief Financial Officer
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics to Participate in the TD Cowen Radiopharmaceutical Innovation Summit
From Bicycle Therapeutics plc
Via Business Wire
Analyst Ratings for Bicycle Therapeutics
 
Via Benzinga
What 8 Analyst Ratings Have To Say About Bicycle Therapeutics
 
Via Benzinga
Looking Into Bicycle Therapeutics's Return On Capital Employed
 
Via Benzinga
Bicycle Therapeutics to Participate in the Jefferies Healthcare Conference
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics and Orano Med Present Preclinical Bicycle® Radio-Conjugate Data at TIDES 2023
From Bicycle Therapeutics plc
Via Business Wire
Bayer and Bicycle Therapeutics Enter Strategic Collaboration for Development of Novel Targeted Radionuclide Therapies in Oncology
From Bayer
Via Business Wire
Bicycle Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Announces Collaboration With the German Cancer Research Center, to Discover and Develop Wholly Owned Bicycle® Radio Conjugates for a Range of Oncology Targets
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics to Present at the 2023 AACR Annual Meeting
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Enhances Leadership Team with Key Appointments
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Announces a Strategic Collaboration with Novartis to Discover, Develop and Commercialize Bicycle® Radio-Conjugates
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics to Participate in Upcoming Investor Conferences
From Bicycle Therapeutics
Via Business Wire
Bicycle Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Announces Phase I Dose Escalation Results from Ongoing Phase I/II Study of BT8009
From Bicycle Therapeutics
Via Business Wire
Bicycle Therapeutics to Participate in the SVB Securities Global Biopharma Conference
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics to Present End of Dose Escalation Data from Ongoing Phase I/II Study of BT8009 at the 2023 ASCO Genitourinary (GU) Cancers Symposium
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Announces FDA Fast Track Designation Granted to BT8009 for the Treatment of Adult Patients with Previously Treated Locally Advanced or Metastatic Urothelial Cancer
From Bicycle Therapeutics plc
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
 
Via Benzinga
Bicycle Therapeutics to Present Five Posters Highlighting Preclinical Data from its Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®) Programs at the SITC 37th Annual Meeting
From Bicycle Therapeutics
Via Business Wire
Bicycle Therapeutics Announces First Patient Dosed in BT8009 Phase II Expansion Cohorts and Provides Program Update
From Bicycle Therapeutics
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.